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Supplementary table 1. Demographic and clinical data for Parkinson’s disease participants who 






 Clinical assessments 
Age, years 65.36 (9.86) 69.2 (12.0) t=1.68, 0.095 
Sex, Males ⸣ 45 (65) 21 (70) Χ2=0.07, 0.800 
Height, m 1.70 (0.09) 1.70 (0.07) t=-0.30, 0.767 
Mass, kg 78.04 (15.09) 80.98 (15.25) t=0.89 0.378 
Education, years 13.7 (3.8) 12.7 (4.5) U=812, 0.239 
NART 115.6 (10.7) 116.0 (9.3) U=975, 0.931 
MoCA 25.6 (3.6) 24.3 (3.7) U=731, 0.123 
MMSE 28.8 (1.1) 28.4 (1.6) U=918, 0.353 
GDS-15 2.6 (2.3) 2.7 (1.9) U=949, 0.507 
MDS-UPDRS III 24.5 (10.2) 26.8 (10.0) t=1.02, 0.312 
H&Y Stage ⸣ 19 I (27), 39 II 
(57), 11 III (16) 
4 I (13), 19 II (63), 
7 III (23) 
Χ2=1.77, 0.414 
Disease duration, months 6.1 (4.1) 7.5 (6.0) U=930, 0.422 
LEDD 152 (113) 214 (154) U=820, 0.098 
Gait assessments 
Step velocity, ms-1 1.15 (0.21) 1.07 (0.23) F(1,95)=1.4, p=0.245 
Step length, m 0.64 (0.09) 0.60 (0.11) F(1,95)=1.1, p=0.300 
Swing time sd, ms 16.86 (4.92) 19.66 (7.77) F(1,95)=2.0, p=0.159 
Step time sd, ms 18.25 (5.60) 20.86 (7.77) F(1,95)=2.1, p=0.149 
Stance time sd, ms 21.94 (8.73) 26.30 (11.33) F(1,95)=3.4, p=0.068 
Step velocity sd, ms-1 0.05 (0.01) 0.06 (0.02) F(1,95)=0.8, p=0.375 
Step length sd, m 0.02 (0.01) 0.02 (0.01) F(1,95)=2.4, p=0.128 
Step time, ms 561.36 (47.18) 570.00 (54.19) F(1,95)=0.7, p=0.405 
Swing time, ms 394.81 (33.58) 393.07 (31.99) F(1,95)=0.01, p=0.917 
Stance time, ms 728.27 (74.40) 747.51 (84.84) F(1,95)=1.1, p=0.304 
Step time asym, ms 19.77 (19.05) 20.61 (23.21) F(1,95)=0.3, p=0.558 
Swing time asym, ms 16.26 (15.09) 15.60 (16.59) F(1,95)=0.01, p=0.913 
Stance time asym, ms 15.81 (14.88) 14.74 (15.34) F(1,95)=0.003, p=0.959 
Step length asym, m 0.02 (0.02) 0.03 (0.02) F(1,95)=1.1, p=0.291 
Step width, m 0.09 (0.03) 0.10 (0.03) F(1,95)=1.4, p=0.240 
Step width sd, m 0.02 (0.01) 0.02 (0.01) F(1,95)=0.03, p=0.861 
cBF assessments 
TIV normalised Ch4p volume 0.002 (0.062) -0.018 (0.074) F1,95 = 0.23, p=0.630 
TIV normalised Ch4 (NBM) volume -0.001 (0.046) -0.014 (0.056) F1,95 = 0.06, p=0.813 
TIV normalised Ch1-2 volume 0.002 (0.054) -0.014 (0.059) F1,95 = 0.26, p=0.614 
[GDS-15, Geriatric Depression Scale; NART, National Adult Reading Test; MoCA, Montreal 
Cognitive Assessment; MMSE, Mini-Mental State Examination; MDS-UPDRS III, Movement 
Disorders Society Unified Parkinson’s disease Rating Scale part three; H&Y, Hoehn and Yahr; 
LEDD, Levodopa Equivalent Daily Dose; sd, standard deviation; asym, asymmetry; cBF, cholinergic 
basal forebrain [NB values are TIV normalised using ANCOVA]. All figures are mean (standard 
deviation) except ⸣ where figures are n(%). At baseline, n=6 did not complete MoCA and n=1 did not 




Supplementary table 2. Bivariate Pearson correlations between gait characteristics and total 
intracranial volume normalised cBF volumes.  
 Parkinson’s Disease Controls 
Ch4p Ch4 Ch1-2 Ch4p Ch4 Ch1-2 
Step velocity .207 (.040) .230 (.022) .218 (.030) .248 (.092) .161 (.279) .147 (.325) 
Step length .261 (.009) .290 (.004) .233 (.020) .272 (.065) .048 (.747) .077 (.606) 
Swing time sd -.116 (.253) -.081 (.423) -.068 (.501) -.058 (.700) -.042 (.781) -.133 (.374) 
Step time sd -.041 (.689) .005 (.957) .011 (.912) -.236 (.111) -.182 (.220) -.191 (.198) 
Stance time sd -.034 (.741) -.021 (.839) -.049 (.633) -.208 (.160) -.154 (.302) -.216 (.145) 
Step velocity sd -.004 (.970) .027 (.788) .016 (.876) -.182 (.221) -.084 (.572) -.252 (.087) 
Step length sd -.147 (.148) -.139 (.171) -.072 (.478) -.144 (.333) -.041 (.784) -.193 (.193) 
Step time .008 (.937) .012 (.904) -.064 (.528) .028 (.850) -.120 (.421) -.095 (.527) 
Swing time .164 (.105) .159 (.116) .060 (.557) .097 (.515) -.047 (.755) -.017 (.912) 
Stance time -.059 (.565) -.050 (.620) -.105 (.299) -.010 (.948) -.149 (.318) -.126 (.397) 
Step time asy .113 (.266) .061 (.550) -.022 (.826) -.007 (.965) -.051 (.733) -.172 (.248) 
Swing time asy .099 (.329) .096 (.345) .038 (.711) -.011 (.941) .075 (.615) .073 (.624) 
Stance time asy .073 (.471) .042 (.682) -.012 (.909) -.025 (.867) .108 (.468) .068 (.649) 
Step length asy -.040 (.691) -.005 (.962) .089 (.379) -.116 (.436) -.198 (.182) -.155 (.297) 
Step width -.069 (.499) -.018 (.857) .060 (.555) -.056 (.709) -.050 (.738) .123 (.409) 
Step width sd -.142 (.162) -.034 (.741) -.144 (.155) -.125 (.403) -.193 (.194) -.019 (.898) 
[All values are presented as r (p). Significant correlations (under Benjamini-Hochberg correction) are 
highlighted and in bold.] 
Supplementary table 3. Age and sex adjusted partial correlations between gait characteristics and 
total intracranial volume normalised cBF volumes.  
[All values are presented as r (p).]
 Parkinson’s Disease Controls 
Ch4p Ch4 Ch1-2 Ch4p Ch4 Ch1-2 
Step velocity .018 (.858) .058 (.572) .067 (.514) .181 (.235) .094 (.539) .110 (.474) 
Step length .009 (.931) .058 (.573) .020 (.846) .163 (.284) -.049 (.749) -.011 (.941) 
Swing time sd .039 (.707) .071 (.489) .064 (.536) -.001 (.993) .024 (.876) -.118 (.441) 
Step time sd .061 (.555) .113 (.270) .101 (.323) -.176 (.246) -.121 (.427) -.162 (.289) 
Stance time sd .070 (.495) .081 (.431) .031 (.767) -.127 (.407) -.087 (.569) -.178 (.243) 
Step velocity sd .044 (.668) .082 (.423) .058 (.573) -.116 (.448) -.050 (.746) -.223 (.142) 
Step length sd .022 (.827) .019 (.852) .078 (.445) -.017 (.910) .098 (.522) -.151 (.321) 
Step time -.020 (.846) -.021 (.838) -.108 (.295) -.078 (.609) -.180 (.238) -.194 (.201) 
Swing time .022 (.832) .017 (.869) -.085 (.409) -.094 (.539) -.181 (.235) -.144 (.346) 
Stance time -.036 (.725) -.034 (.738) -.101 (.323) -.059 (.700) -.159 (.298) -.193 (.205) 
Step time asy -.064 (.534) -.123 (.230) -.195 (.056) -.128 (.401) -.131 (.392) -.240 (.113) 
Swing time asy -.006 (.950) -.005 (.962) -.060 (.559) .064 (.677) .145 (.341) .106 (.488) 
Stance time asy -.046 (.654) -.078 (.446) -.123 (.229) -.017 (.914) .126 (.411) .077 (.614) 
Step length asy -.052 (.612) -.014 (.894) .108 (.294) .017 (.911) -.038 (.803) -.149 (.330) 
Step width -.127 (.215) -.064 (.536) .042 (.686) -.053 (.731) -.003 (.982) .126 (.410) 
Step width sd .039 (.701) .166 (.105) -.004 (.968) -.013 (.930) -.073 (.635) .019 (.901) 
Supplementary table 4. Clinical characteristics of participants at baseline and 36 months. 
 
 Parkinson’s disease Control 
Characteristic Baseline 36 months Statistic, p-value Baseline 36 months  Statistic, p-value 
N 99 69 - 47 35 - 
Age, years 66.53 (10.69) 68.42 (9.86) t=-81.6, p<.001* 65.82 (8.02) 70.20 (6.10) t=-83.3, p<.001* 
Sex, Males ⸣ 66 (67) 45 (65) - 29 (62) 21 (60) - 
Height, m 1.70 (0.08) 1.69 (0.09) t=3.60, p=.001* 1.71 (0.10) 1.71 (0.09) t=1.49, p=.145 
Mass, kg 78.93 (15.12) 79.05 (17.03) t=-1.18, p=.244 79.53 (13.05) 79.89 (13.00) t=1.17, p=.252 
Education, years 13.4 (4.0) - - 13.8 (3.7) - - 
NART 115.7 (10.3) - - 117.7 (7.9) - - 
MoCA 25.2 (3.6) 26.3 (3.6) W63=-1.50, p=.134 27.7 (2.0) 28.3 (1.9) W35=-1.20, p=.230 
MMSE 28.7 (1.3) 28.4 (2.0) W69=-2.12, p=.034* 29.3 (0.9) 29.45(1.0) W35=-0.19, p=.850 
GDS-15 2.6 (2.2) 2.5 (2.2) W69=-0.59, p=.554 0.9 (1.2) 0.8 (1.2) W35=-0.87, p=.931 
MDS-UPDRS III 25.2 (10.2) 35.8 (11.8) W69=-6.14, p<.001* - - - 
H&Y Stage ⸣ 23 I (23), 58 II 
(59), 18 III (18) 
1 I (1), 61 II 
(88), 7 III (10) 
- - - - 
Disease duration, 
months 
6.5 (4.8) - - - - - 
LEDD (mg/day) 171 (129) 524 (258) W69=-7.06, p<.001* - - - 
- [GDS-15, Geriatric Depression Scale; NART, National Adult Reading Test; MoCA, Montreal Cognitive Assessment; MMSE, Mini-
Mental State Examination; MDS-UPDRS III, Movement Disorders Society Unified Parkinson’s Disease Rating Scale; H&Y, Hoehn and 
Yahr; LEDD, Levodopa Equivalent Daily Dose. All figures are mean (standard deviation) except ⸣ where figures are n(%). At baseline, 
n=6 did not complete MoCA and n=1 did not complete NART in the Parkinson’s group. In controls, n=1 participant did not have height 
measured, nor completed MoCA or GDS-15 assessment at 36 months. Significant differences are in bold and denoted by *. NB, of the 18 
















Supplementary Figure 2. Radar plot illustrating the pattern of gait impairment at baseline. 
 
[Var, variability; Asy, asymmetry. The central line represents control data. Deviations from 
zero along the axes radiating from the centre of the plot represent how many standard 
deviations (z score based on control baseline means and standard deviations) the Parkinson’s 
disease group differed from controls. Gait variables are organised by domain (Lord et al. 














Supplementary Figure 3. Distribution of gait characteristics at each assessment 
 
 
 
 
